Sanofi, Bristol to Settle Plavix Patent Suit
- Share via
Sanofi-Aventis and Bristol-Myers Squibb Co. said they had settled a dispute with generic drug maker Apotex Inc. that could keep patent protection on their multibillion-dollar blood thinner Plavix until 2011.
A trial involving the disputed Plavix patent had been set to begin in June in U.S. District Court in New York.
Sanofi and Bristol-Myers said they had approached Indian generic drug maker Dr. Reddy’s Laboratories Ltd. to discuss a similar settlement.
Under terms of the proposed Apotex settlement, Sanofi-Aventis would grant Apotex a royalty-bearing license to sell clopidogrel bisulfate in the U.S. once the patent expires in 2011. Clopidogrel is the chemical name for Plavix.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
